Park resigns from Isotechnika as ILJIN takes control
This article was originally published in Scrip
Executive Summary
Daniel Park has resigned his position as chief business officer of Isotechnika Pharma, a biopharmaceutical company developing immunomodulating therapeutics, to avoid potential conflicts of interest that may arise as a result of his position as executive vice-president of ILJIN Life Science, which Mr Park has informed Isotechnika, intends to "increase its level of control within the company". Mr Park will remain on Isotechnika's board of directors.